Bladder Cancer — Trials, FDA Actions & Pivotal Research
16 updates aggregated from openFDA and ClinicalTrials.gov, covering trial milestones, FDA actions, and pivotal publications about Bladder Cancer.
Synced daily from openFDA and ClinicalTrials.gov. Last sync: .
Drugs with Bladder Cancer trials
Recruiting trials by city
Cities where Bladder Cancer trials in our archive had recruiting sites. Each link lists every currently recruiting paid clinical trial at that location.
Updates
2026
- Results postedBladder Cancer: P3-BC Decision Support Tool Shows Acceptability· Apr 24, 2026
- Results postedPembrolizumab Combination Trial for Solid Tumors Reports DLTs at High Dose· Mar 27, 2026· drug: Pembrolizumab
- Results postedBladder Cancer: Recovery Support Intervention Shows Modest QoL Benefit· Mar 19, 2026
- Primary completionNivolumab Phase 3 MIBC Trial Reaches Primary Completion· Feb 16, 2026· drug: Nivolumab
- Primary completionPembrolizumab Phase 3 Trial for Bladder Cancer Completes Primary Data Collection· Jan 26, 2026· drug: Pembrolizumab
- Results postedBladder Cancer: Adaptive Weekly Radiotherapy Shows Better Local Control, Fewer…· Jan 15, 2026
2025
- Results postedMedtronic Hugo RAS System: Urologic Surgery Trial Results Posted· Nov 25, 2025
- Results postedBladder Cancer: CISTO Trial Posts Quality of Life Outcomes for Treatment Options· Nov 4, 2025
- Primary completionPembrolizumab Phase 3 Trial for Bladder Cancer Completes Primary Data Collection· Oct 27, 2025· drug: Pembrolizumab
- Results postedPembrolizumab Shows Positive Immunogenomic Marker Changes in Bladder Cancer· Oct 7, 2025· drug: Pembrolizumab
- Results postedNivolumab Combination Improves Overall Survival in Urothelial Cancer· Sep 18, 2025· drug: Nivolumab
- Results postedPembrolizumab/Enoblituzumab Combination Reports Low DLTs in Refractory Cancers· Aug 11, 2025· drug: Pembrolizumab
- Results postedNivolumab Monotherapy Shows 23% Objective Response in Bladder Cancer· Jul 22, 2025· drug: Nivolumab
- Primary completionAtezolizumab Trial for High-Risk Bladder Cancer Reaches Primary Completion· Jun 30, 2025· drug: Atezolizumab
- Primary completionAtezolizumab Phase 3 Trial for MIBC Reaches Primary Completion· Jun 15, 2025· drug: Atezolizumab
- Results postedPembrolizumab with Chemo Shows High Durable Response in Small Cell Bladder…· Jun 10, 2025· drug: Pembrolizumab